Summary of proliferative responses to RhD protein and RhD peptides by patients with CLL with secondary AIHA (CLL + AIHA)
Patient . | Purified RhD protein-induced proliferation . | Rh-specific peptides stimulating proliferation* . |
|---|---|---|
| 1 | Y | 2, 3, 8, 11, 18, 20, 27, 33, 34, 35, 44, 46, 48, 50, 52, 55, 62, 67, 68 |
| 2 | Y | 2, 5, 26, 34, 57 |
| 3 | Y | 3, 9, 10, 22, 28, 37 |
| 4 | Y | 1, 23 |
| 5 | Y | 19, 68 |
| 6 | Y | NT |
| 7 | NA | 12, 20, 50, 58, 63 |
| 8 | NA | 2, 3, 4, 20, 21, 23, 44, 52, 54, 63 |
| 9 | Y | NT |
| 10 | Y | 5, 6, 9, 17, 18, 21, 30 |
| 11 | Y | 5, 57 |
| 12 | Y | 21, 46 |
Patient . | Purified RhD protein-induced proliferation . | Rh-specific peptides stimulating proliferation* . |
|---|---|---|
| 1 | Y | 2, 3, 8, 11, 18, 20, 27, 33, 34, 35, 44, 46, 48, 50, 52, 55, 62, 67, 68 |
| 2 | Y | 2, 5, 26, 34, 57 |
| 3 | Y | 3, 9, 10, 22, 28, 37 |
| 4 | Y | 1, 23 |
| 5 | Y | 19, 68 |
| 6 | Y | NT |
| 7 | NA | 12, 20, 50, 58, 63 |
| 8 | NA | 2, 3, 4, 20, 21, 23, 44, 52, 54, 63 |
| 9 | Y | NT |
| 10 | Y | 5, 6, 9, 17, 18, 21, 30 |
| 11 | Y | 5, 57 |
| 12 | Y | 21, 46 |
NA indicates not applicable (RhD-negative patient); NT, not tested.
PBMCs from patients tested with the appropriate panel of synthetic RhD or Rhce peptides to match phenotype (Rhce panel tested in patients CLL + AIHA 7 and 8).